Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Lethal occipital encephalocele-skeletal dysplasia syndrome is a rare, genetic, bone development disorder characterized by occipital and parietal bone hypoplasia leading to occipital encephalocele, calvarial mineralization defects, craniosynostosis, radiohumeral fusions, oligodactyly and other skeletal anomalies (arachnodactyly, terminal phalangeal aplasia of the thumbs, bilateral absence of the great toes, pronounced bilateral angulation of femora, shortened limbs, advanced osseous maturation). Fetal death in utero is associated.
Features include: Oligodactyly, Arachnodactyly, Craniosynostosis, and Occipital encephalocele and 2 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Head and neck | 1 | Craniosynostosis |
CYP26B1 encodes cytochrome P450 family 26 subfamily B member 1 (512 aa). A cytochrome P450 monooxygenase involved in the metabolism of retinoates (RAs), the active metabolites of vitamin A, and critical signaling molecules in animals. Highest expression in Brain Cerebellar Hemisphere (65.3 TPM) and Brain Cerebellum (56.0 TPM).
Lethal occipital encephalocele-skeletal dysplasia syndrome is associated with mutations in the CYP26B1 gene on chromosome 2.
The CYP26B1 protein participates in Defective CYP26B1 causes RHFCA, Defective CYP26B1 does not 4-hydroxylate atRA, and CYP26A1,B1,C1 4-hydroxylate atRA pathways.
CYP26B1 is classified as a druggable target (Cytochrome P450, Druggable Genome, and Enzyme categories) with score 10.4.
Genetic testing for CYP26B1 is available. Testing is considered confirmatory for diagnosis.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for lethal occipital encephalocele-skeletal dysplasia syndrome.
1 publication has been identified in PubMed for lethal occipital encephalocele-skeletal dysplasia syndrome. Research spans Case Report / Case Series (100%).
Moulehi K (2025). [PMID: 41858965](https://pubmed.ncbi.nlm.nih.gov/41858965/). *Pan Afr Med J*. [Case Report / Case Series]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 5:41 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center